182 related articles for article (PubMed ID: 15351209)
1. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
2. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
4. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
Schmitz T; Kleinkauf N; Klempa B; Ringe H; Varnholt V; Grosch-Wörner I
Pediatr Infect Dis J; 2006 Mar; 25(3):275-6. PubMed ID: 16511398
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
6. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
9. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
[TBL] [Abstract][Full Text] [Related]
10. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
11. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
Gatanaga H; Hachiya A; Kimura S; Oka S
Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
[TBL] [Abstract][Full Text] [Related]
12. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
13. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
van Zyl GU; Claassen M; Engelbrecht S; Laten JD; Cotton MF; Theron GB; Preiser W
J Med Virol; 2008 Jun; 80(6):942-6. PubMed ID: 18428139
[TBL] [Abstract][Full Text] [Related]
15. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
16. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of natural selection in the reverse transcriptase gene of HIV-1 in the presence and absence of antiretroviral therapy.
de S Leal E; Holmes EC; Zanotto PM
Virology; 2004 Aug; 325(2):181-91. PubMed ID: 15246258
[TBL] [Abstract][Full Text] [Related]
20. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
